Meeting
2014 Breast Cancer Symposium
Primary analysis of the prospective, randomized, phase II trial of GP2+GM-CSF vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
Authors
Erika J Schneble
San Antonio Military Medical Center, San Antonio, TX
Erika J Schneble , Sonia A. Perez , James L. Murray , John S. Berry IV, Alfred F. Trappey III, Timothy J. Vreeland , Diane F. Hale , Julia M. Greene , Guy T. Clifton , Alexandros Ardavanis , Jennifer Keating Litton , Sathibalan Ponniah , Nathan M. Shumway , Michael Papamichail , George Earl Peoples , Elizabeth Ann Mittendorf
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Risk Assessment, Prevention, Early Detection, Screening, and Systemic Therapy
Track
Systemic Therapy,Risk Assessment, Prevention, Early Detection, and Screening
Sub Track
HER2+
Clinical Trial Registration Number
NCT00524277
Citation
J Clin Oncol 32, 2014 (suppl 26; abstr 134)
DOI
10.1200/jco.2014.32.26_suppl.134
Abstract #
134
Poster Bd #
A4
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Primary analysis of the prospective, randomized, single-blinded phase II trial of AE37 vaccine versus GM-CSF alone administered in the adjuvant setting to high-risk breast cancer patients.
First Author: Elizabeth Ann Mittendorf
Poster
2017 ASCO Annual Meeting
Subgroup efficacy evaluation of the AE37 HER2 vaccine in breast cancer patients in the adjuvant setting.
First Author: Kaitlin M. Peace
First Author: Snehal Patel
Poster
2011 ASCO Annual Meeting
Sequential administration of trastuzumab and a CD8 T-cell-eliciting HER2/neu peptide vaccine in patients with breast cancer compared to trastuzumab alone.
First Author: A. K. Sears